reslizumab (Cinqair)

Indications

• maintenance treatment of severe asthma in patients >= 18 years of age (for use in conjuction with other agents)
• history of severe asthma exacerbations despite appropriate asthma therapy

Dosage

• administered once every 4 weeks via IV infusion

Adverse effects

• hypersensitivity reactions
• most common adverse effects in clinical trials
  • anaphylaxis
  • cancer
  • myalgia

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• recombinant humanized IL5 monoclonal antibody (antagonist)
• reduces blood eosinophils

More general terms

• pharmaceutical monoclonal antibody
• recombinant protein; chimer
• antiasthmatic agent